Lista de obras - David J Lloyd - Dominio Público Uruguay

A gain-of-function mutation in adenylate cyclase 3 protects mice from diet-induced obesity

artículo científico publicado en 2014

A mutation in Ampd2 is associated with nephrotic syndrome and hypercholesterolemia in mice

scientific journal article

A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice

artículo científico publicado en 2009

A volumetric method for quantifying atherosclerosis in mice by using microCT: comparison to en face

artículo científico publicado en 2011

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

artículo científico publicado en 2018

Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.

artículo científico publicado en 2009

Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors

artículo científico publicado en 2013

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism

artículo científico publicado en 2020

Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Binding: Strategic Use of a N → S (nN → σ*S-X) Interaction for Conformational Constraint

artículo científico publicado en 2015

Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts

artículo científico publicado en 2005

FGF21 promotes metabolic homeostasis via white adipose and leptin in mice

artículo científico publicado en 2012

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

artículo científico publicado en 2008

Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr.

artículo científico

Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes

artículo científico publicado en 2016

Identification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in mice

scientific journal article

LMNA, encoding lamin A/C, is mutated in partial lipodystrophy.

artículo científico publicado en 2000

Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy

article

Lessons from lipodystrophy:LMNA, encoding lamin A/C, in HIV therapy-associated lipodystrophy

article

Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance

artículo científico publicado en 2009

Molecular targeting of the GK-GKRP pathway in diabetes

artículo científico publicado en 2014

New variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification

artículo científico publicado en 2009

Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue.

artículo científico publicado en 2015

Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice

artículo científico publicado en 2011

SUN1 interacts with nuclear lamin A and cytoplasmic nesprins to provide a physical connection between the nuclear lamina and the cytoskeleton

artículo científico publicado en 2006

Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis

artículo científico publicado en 2015

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept

artículo científico publicado en 2014

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles

artículo científico publicado en 2014

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N'-arylpiperazine series

artículo científico publicado en 2014

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket

artículo científico publicado en 2014

Lista de obras de David J Lloyd

A gain-of-function mutation in adenylate cyclase 3 protects mice from diet-induced obesity

A mutation in Ampd2 is associated with nephrotic syndrome and hypercholesterolemia in mice

A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice

A volumetric method for quantifying atherosclerosis in mice by using microCT: comparison to en face

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.

Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism

Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Binding: Strategic Use of a N → S (nN → σ*S-X) Interaction for Conformational Constraint

Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts

FGF21 promotes metabolic homeostasis via white adipose and leptin in mice

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr.

Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes

Identification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in mice

LMNA, encoding lamin A/C, is mutated in partial lipodystrophy.

Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy

Lessons from lipodystrophy:LMNA, encoding lamin A/C, in HIV therapy-associated lipodystrophy

Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance

Molecular targeting of the GK-GKRP pathway in diabetes

New variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification

Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue.

Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice

SUN1 interacts with nuclear lamin A and cytoplasmic nesprins to provide a physical connection between the nuclear lamina and the cytoskeleton

Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N'-arylpiperazine series

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket